Compare ResMed Inc. (RMD) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Twist Bioscience Corp — how do they compare? ResMed Inc. trades at $220 (market cap $32.61B), while Twist Bioscience Corp trades at $125.69 (market cap $7.72B). The key difference: ResMed Inc. is far larger — about 4.2× Twist Bioscience Corp's market cap, and ResMed Inc. pays a 1.17% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| RMD | TWST | |
|---|---|---|
Market Cap | $32.61B | $7.72B |
Sector | Health | Health |
52-Week High | $293.73 | $124.88 |
52-Week Low | $182.82 | $24.16 |
Enterprise Value | $31.97B | $7.65B |
Dividend Yield | 1.17% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
